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Abstract
Objective Improvement of visual ﬁeld defects con-
tinues even years after the initial surgical treatment.
Because this process of continuing improvement has
not been documented for visual acuity, we audited our
data to explore the pattern of recovery of visual acuity
until 1 year after transsphenoidal surgery for non-
functioning pituitary macroadenoma.
Design Retrospective follow-up study.
Patients Forty-three patients (mean age 56 ± 14 years),
treated by transsphenoidal surgery for non-functio-
ning pituitary macroadenoma, were included in this
analysis.
Results Visual acuity improved signiﬁcantly within
3 months after transsphenoidal surgery. The mean
visual acuity increased from 0.65 ± 0.37 to 0.75 ± 0.36
(P < 0.01) (right eye), and from 0.60 ± 0.32 to
0.82 ± 0.30 (P < 0.01) (left eye). Visual acuity was
improved 1 year after transsphenoidal surgery com-
pared to the 3 months postoperative values. The mean
visual acuity increased from 0.75 ± 0.36 to 0.82 ± 0.34
(P < 0.05) (right eye), and from 0.82 ± 0.30 to
0.88 ± 0.27 (P < 0.05) (left eye).
Conclusion Visual acuity improves progressively
after surgical treatment for non-functioning pituitary
macroadenomas, at least within the ﬁrst year after
transsphenoidal surgery.
Keywords Non-functioning macroadenoma 
Surgery  Visual acuity
Introduction
Non-functioning pituitary macroadenomas (NFMA)
are the most prevalent macroadenomas [1, 2]. Patients
with NFMA mainly present with decreased visual
acuity, visual ﬁeld defects and hypopituitarism, caused
by mass effects of the tumor [3–5]. Transsphenoidal
surgery is the treatment of choice, resulting in
improvement of visual ﬁeld defects in 75–100% of all
patients [3–5]. Accordingly, visual acuity improves in
the majority of patients [6–10], although visual ﬁeld
defects and visual acuity may worsen in a limited
number of patients after surgery [6, 7, 9, 10].
The process of visual ﬁelds recovery starts directly
after surgery and can already be documented on the
second postoperative day [11]. This process of
recovery is probably due to restoration of the
velocity of conduction. However, improvement of
visual ﬁeld defects continues even years after the
initial surgical treatment [12, 13]. Although a reduced
visual acuity is correlated with the extent of visual
ﬁeld defects [13, 14], postoperative changes in visual
acuity do not parallel changes in visual ﬁelds in every
case [6].
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improvement, has only been observed for visual ﬁeld
defects, but not for visual acuity [12]. This is, however,
clinically relevant, since improvement of minor visual
ﬁeld defects can occur unnoticed, whereas improve-
ment in visual acuity is almost invariably noticed, and
can potentially overcome thresholds to previous
impairments in daily life. We therefore audited our
data to explore the pattern of recovery of visual acuity
until 1 year after transsphenoidal surgery for non-
functioning pituitary macroadenoma.
Patients and methods
Patient selection
Forty-three patients, mean age 56 ± 14 years, were
included in this retrospective analysis. In order to ob-
tain a homogenous cohort for assessment, the inclusion
criteria were the following:
1. Compression of the optic chiasm on MRI by the
pituitary tumor prior to surgery
2. Transsphenoidal surgery for non-functioning pitu-
itary macroadenoma (diameter > 1 cm) for
decompression of the optic chiasm
3. Assessment of visual acuity at least once before
surgery, and at least twice in the ﬁrst year after
surgery
4. The availability of two postsurgical MR scans,
within a time frame of maximal 3 months of the
ophtalmological assessments
We did not restrict the inclusion criteria to patients
with visual ﬁeld defects, but also included patients
with clear compression of the optic chiasm without
decreased visual function, for two reasons. First, we
were interested in the pattern of change in visual
function prior to surgery. Second, it is, at least the-
oretically, possible that in patients with compression
of the optic chiasm, surgical treatment may decrease
visual function. To overcome the potential effect of
postoperative tumor-regrowth on visual outcome,
patients were excluded from analysis if the 1 year
post-operative scans revealed growth of residual
tumor.
For complete assessment, we reviewed the patient
records of all departments involved in the treatment
of NFMA (Endocrinology, Neurosurgery, Ophthal-
mology). Endocrine (pituitary function) and oph-
thalmologic data (visual acuity and visual ﬁelds) were
assessed before surgery, 3 and 12 months after
surgery. An MRI was performed before surgery,
3–6 months and 12–15 months after surgery.
Transsphenoidal surgery was performed by one of
two neurosurgeons
Corrected visual acuity was determined by the
Snellen chart [15, 16] and was scored for both eyes.
Visual ﬁelds were assessed by Humphrey perimetry in
all patients. Goldman perimetry was used as an addi-
tional tool to assess peripheral visual ﬁeld defects. To
increase the reliability of the visual ﬁeld testing,
assessment of the visual ﬁelds, and thereby also visual
acuity, was preferably performed twice prior to surgical
treatment. However, surgical treatment was not
delayed due to double ophthalmologic testing in pa-
tients with severe impaired visual acuity.
Deﬁnitions
The diagnosis of non-functioning pituitary macroade-
noma was based on two criteria: the presence of a
pituitary macroadenoma (>1 cm) on MRI, and the
absence of overproduction of any of the pituitary
hormones. In all cases the diagnosis was histologically
conﬁrmed. Tumor size was classiﬁed according to
Hardy [17]. Tumor extension was classiﬁed as supra-
sellar (Hardy II
0, A, B, C) or parasellar/infrasellar
(Hardy II
D,E, Hardy III
0-E and Hardy IV
0-E).
In all patients, visual acuity was scored on a scale
between 0 and 1.25. Visual ﬁeld defects were scored
semi-quantitative and classiﬁed as mild, moderate or
severe. Visual ﬁeld defects were classiﬁed as mild, if
there were peripheral defects in only one quadrant.
Defects were classiﬁed as moderate if the upper
quadrants were affected, whereas in combined upper
and lower quadrant ﬁeld defects, these were classiﬁed
as severe.
Growth hormone (GH) deﬁciency was deﬁned as
an insufﬁcient rise in GH levels (absolute va-
lue < 3 lg/l) after stimulation during an insulin tol-
erance test (ITT). When secondary amenorrhoea was
present for more than 1 year premenopausal women
were deﬁned asLH/FSH deﬁcient. Postmenopausal
women were deﬁned as LH/FSH deﬁcient, when
gonadotropin levels were below the normal post-
menopausal range (LH< 10 U/l, FSH < 30 U/l). In
men, LH/FSH deﬁciency was deﬁned, as a testoster-
one level below the reference range (8.0 nmol/l).
TSH deﬁciency was deﬁned as a total or free T4 level
below the reference range. ACTH deﬁciency was
deﬁned as a basal cortisol level at 8.00 AM of
<0.12 lmol/l and/or an insufﬁcient increase in cortisol
levels (absolute value < 0.55 lmol/l) after an ITT.
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123Statistical analysis
The paired t-test was used for paired samples. SPSS
software version 12.0 (SPSS Inc., Chicago, IL, USA)
was used. A P-value of <0.05 was considered statisti-
cally signiﬁcant.
Results
Preoperative patient characteristics (Table 1)
Forty-three patients, 51% male, were included in this
study. Radiological imaging by MRI revealed a mac-
roadenoma in all patients, with suprasellar extension in
100% and parasellar/infrasellar extension in 42% of
cases. Hypopituitarism was present in 79% of all
patients, and panhypopituitarism in 23%.
Pre-operative assessment of visual function
(Table 1)
Visual ﬁelds were normal in 4 patients. Transsphenoi-
dal surgery in these patients was performed because
compression of the optic chiasm was evident on the
MR scan (n = 4). In these 4 patients visual acuity was
at least 1.0 for both eyes. Of all patients with visual
ﬁeld defects 60% were classiﬁed as severe, 17% as
moderate, and 14% as mild. Mean visual acuity was
0.65 ± 0.37 for the right eye, 0.60 ± 0.32 for the left
eye.
Visual acuity was assessed twice before surgery in 34
patients (79% of total). The median time between the
ﬁrst and the second pre-surgical assessment was
4 weeks (range 1–45). No signiﬁcant decrease in visual
acuity was observed within this time period. The mean
visual acuity for the two pre-surgical assessments was:
0.65 ± 0.37 vs. 0.66 ± 0.38 (right eye), and 0.60 ± 0.32
vs. 0.62 ± 0.33 (left eye). Moreover, no decrease in
visual acuity was observed in patients (n = 13) with a
time interval of >8 weeks between the ﬁrst and the
second pre-surgical assessment. In 4 of these patients
there were no visual ﬁeld defects.
Surgical treatment
All patients were treated by transsphenoidal surgery.
Repeat surgery within 6 months after initial treatment
was performed twice (large residual tumor mass
(n = 1) and persisting liquor leakage (n = 1)). Repeat
surgery was performed by transcranial approach.
Transsphenoidal surgery was followed by radio-
therapy in 10 patients in order to prevent recurrence.
Patients received 40 Gy (n =5 )o r4 6G y( n = 5).
Three months postoperative assessment of visual
function
After transsphenoidal operation in patients with pre-
operative visual ﬁeld defects improvement was
observed in 60% and normalization of the visual ﬁelds
in 30%. In 1 patient there was a slight increase in visual
ﬁeld defects.
Visual acuity improved signiﬁcantly 3 months after
transsphenoidal surgery (Fig. 1). The mean visual
acuity increased from 0.65 ± 0.37 to 0.75 ± 0.36
(P < 0.01) (right eye), and from 0.60 ± 0.32 to
0.82 ± 0.30 (P < 0.01) (left eye).
One-year postoperative assessment of visual
function
One year after initial surgical therapy visual ﬁeld
defects showed continuous improvement in 36% of
patients, compared to early postoperative results. In
80% of them, this improvement was accompanied by
continuous improvement of visual acuity.
In 56% of all patients (n = 24) visual acuity shows
continuing improvement until 1 year after surgery. In 8
of them, this improvement was not accompanied by
further improvement of visual ﬁeld defects. Visual
acuity was improved 1 year after transsphenoidal sur-
gery compared to the 3 months postoperative values
(Fig. 1). The mean visual acuity increased from
Table 1 Patient characteristics before transsphenoidal surgery
Male/female 22/21
Age (years ± SD) 56 ± 14
Visual acuity
Right eye (mean ± SD) 0.65 ± 0.37
Left eye (mean ± SD) 0.60 ± 0.32
Visual ﬁeld defects
Severe 60%
Moderate 17%
Mild 14%
None 9%
Pituitary function
GH deﬁciency 76%
LH/FSH deﬁciency 69%
ACTH deﬁciency 43%
TSH deﬁciency 36%
Panhypopituitarism 23%
MRI characteristics
Suprasellar extension 100%
Infrasellar/parasellar extension 42%
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1230.75 ± 0.36 to 0.82 ± 0.34 (P < 0.05) (right eye), and
from 0.82 ± 0.30 to 0.88 ± 0.27 (P < 0.05) (left eye).
Discussion
The main aims of surgery in non-functioning pituitary
macroadenoma are restoration of visual acuity and
visual ﬁeld defects by decompression of the optic chi-
asm. Nonetheless, our data indicate that there is no
necessity for immediate decompression, since post-
ponement of surgery for several weeks did not result in
deterioration of visual acuity. Moreover, in this series
of 43 patients, we demonstrated a continuing
improvement of visual acuity until 1 year after trans-
sphenoidal surgery.
There is a signiﬁcant correlation between the
severity of visual loss prior to surgery and persisting
visual ﬁeld defects [9, 13, 14]. In our patients in whom
visual acuity was assessed twice before surgery, no
decrease of visual acuity was observed with a median
time interval between two measurements of 4 weeks.
This indicates that postponing surgery for 1 month
does not negatively inﬂuence visual outcome, which is
in line with the slow growth pattern of non-functioning
adenomas [4]. Nonetheless, the delay of surgery should
not unnecessarily be prolonged because a signiﬁcant,
inverse, correlation between visual outcome and the
prolonged duration of symptoms has been reported [9].
Moreover, especially in patients with rapid loss of
visual function or decreased visual acuity due to
apoplexy, urgent surgical intervention is indicated.
The initial event in the pathogenesis of decreased
visual function in pituitary macroadenomas is com-
pression of the optic chiasm. Nerve compression leads
to decreased conduction and to demyelination. In an
experimental setting, the process of demyelination after
nerve compression has been observed even after 2 days
[18, 19]. In case of continuous nerve compression
remyelination can be observed after several weeks,
although remyelinated ﬁbers do not seem to reach
normal thickness and organization structure, and com-
plete demyelinated ﬁbers co-exist [18, 19]. Re-myelin-
ated ﬁbers restore conduction, at least partially, even if
the causative nerve lesion is still existing [20, 21]. The
improvement of visual dysfunction after surgical treat-
ment is supposed to consist of two, or probably even
three, phases [12]. There is an early phase, comprising
the ﬁrst hours and days after surgery. In this early fast
phase, the improvement is caused by decompression of
the visual pathways, leading to a restoration of signal
conduction. Visual recovery has been demonstrated in
the ﬁrst days after surgical treatment [11, 12]. The
second phase, i.e., delayed recovery, is pathophysio-
logically caused by restoration of axonal transport and
remyelination, and based on remyelination of the optic
nerve vessels. This phase of delayed recovery may last
for several years [12, 13]. A precise boundary between
the end of the fast phase of recovery and the start of the
delayed recovery seems to be artiﬁcial, because these
two phases reﬂect different pathophysiological mecha-
nisms, which may co-existfor acertain time-period. The
contribution of the ﬁrst phase of recovery might be
larger, given the fact that more than 50% of eventual
recovery takes place within the ﬁrst 3 months after
surgery [13].
It is already known that visual acuity improves in the
ﬁrst months after surgical treatment [6–10] and that the
improvement of visual ﬁeld defects is a continuing
process for at least 1 year [12, 13]. Kerrison et al. [12]
showed progressive improvement of visual ﬁelds even
more than 2 years after surgical decompression of the
optic chiasm. However, they did not demonstrate this
same pattern of recovery for visual acuity. This might
be due to the relative small number of patients during
prolonged follow-up. In the present study we
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Fig. 1 The pattern of
improvement of visual acuity
after transsphenoidal surgery
for non-functioning pituitary
macroadenomas (n = 43)
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123demonstrate that also improvement of visual acuity
continued 1 year after surgical treatment.
The clinical consequences of the delayed phase of
recovery for both visual ﬁeld defects and visual acuity
are obvious. Follow-up of patients after surgical
treatment for pituitary macroadenomas should include
ophthalmologic assessment within several weeks after
surgery, as well as subsequent assessments after one
and 2 years, in order to estimate the ﬁnal effect of
surgery on visual function. Moreover, patients should
be told that visual function can continue to improve, at
least until 1 year after surgery. The relevance of these
ﬁndings are obvious and is of importance to all
patients, given the impact of a decreased visual acuity
as an independent predictor for a decreased quality of
life [22, 23]. Moreover, these data are essential in order
to evaluate potential effects of recurrent pituitary
adenomas on visual function.
Ten patients in our series received postoperative
radiotherapy. However, it is unlikely that this treat-
ment affected the results of our study. In a series
reported by Gnanalingham et al. [13], in which 34% of
all patients received postoperative radiotherapy, per-
sistent improvement of visual ﬁeld defects was docu-
mented even years after surgical therapy. In another
series of 21 patients, 2 years after pituitary irradiation,
there were no cases of radiation-induced visual ﬁeld or
visual acuity deterioration [24].
In conclusion, this study demonstrates that the
improvement of visual acuity, after transsphenoidal
treatment for non-functioning pituitary macroadeno-
mas, consists of both an early and a delayed phase of
recovery. After initial post-surgical recovery, a pro-
gressive delayed improvement of visual acuity at least
until 1 year after transsphenoidal surgery, is likely to
occur.
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